Literature DB >> 20722750

The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

M Israr1, D Mitchell, S Alam, D Dinello, J J Kishel, C Meyers.   

Abstract

OBJECTIVE: This study was designed to evaluate the effects of the HIV protease inhibitor lopinavir/ritonavir on gingival epithelium growth, integrity and differentiation.
METHODS: Organotypic (raft) cultures of gingival keratinocytes were established and treated with a range of lopinavir/ritonavir concentrations. To examine the effect of lopinavir/ritonavir on gingival epithelium growth and stratification, haematoxylin and eosin staining was performed. To investigate the effect of this drug on tissue integrity, transmission electron microscopy (TEM) was performed on untreated and drug-treated tissues. Further, immunohistochemical analysis of raft cultures was performed to assess the effect of lopinavir/ritonavir on the expression of key differentiation and proliferation markers including cytokeratins, proliferating cell nuclear antigen (PCNA) and cyclin A.
RESULTS: Lopinavir/ritonavir treatments drastically inhibited the growth of gingival epithelium when the drug was present throughout the growth period of the tissue. When the drug was added on day 8 of tissue growth, lopinavir/ritonavir treatments compromised tissue integrity over time and altered the proliferation and differentiation of gingival keratinocytes. Expression of cytokeratins 5, 14, 10 and 6, PCNA and cyclin A was induced, and their expression patterns were also altered over time in treated rafts.
CONCLUSIONS: The findings of our studies suggest that lopinavir/ritonavir treatments compromised tissue integrity over time and deregulated the cell cycle/proliferation and differentiation pathways, resulting in abnormal epithelial repair and proliferation. Our study provides a model of potential utility in studying the effects of antiretroviral drugs in vitro.
© 2010 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722750      PMCID: PMC3024444          DOI: 10.1111/j.1468-1293.2010.00863.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  48 in total

1.  Gene expression of differentiation-specific keratins (K4, K13, K1 and K10) in oral non-dysplastic keratoses and lichen planus.

Authors:  B K Bloor; S V Seddon; P R Morgan
Journal:  J Oral Pathol Med       Date:  2000-09       Impact factor: 4.253

2.  Effect of highly active antiretroviral therapy on frequency of oral warts.

Authors:  D Greenspan; A J Canchola; L A MacPhail; B Cheikh; J S Greenspan
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

Review 3.  The epidemiology of the oral lesions of HIV infection in the developed world.

Authors:  J S Greenspan; D Greenspan
Journal:  Oral Dis       Date:  2002       Impact factor: 3.511

4.  HIV drug resistance and you. The limitations of drug resistance testing. Many factors influence the results.

Authors:  Trevor Hawkins
Journal:  Posit Aware       Date:  2006

5.  Cytokeratin expression in initial oral mucositis of head and neck irradiated patients.

Authors:  Paulo Rogério Ferreti Bonan; Estela Kaminagakura; Fábio Ramoa Pires; Pablo Agustin Vargas; Oslei Paes de Almeida
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2005-09-19

Review 6.  Intermediate filaments in oral neoplasia. I. Oral cancer and epithelial dysplasia.

Authors:  P R Morgan; L Su
Journal:  Eur J Cancer B Oral Oncol       Date:  1994-05

7.  Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.

Authors:  Mohd Israr; Danielle Mitchell; Samina Alam; Donald Dinello; Joseph J Kishel; Craig Meyers
Journal:  Antivir Ther       Date:  2010

8.  The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults.

Authors:  Jennifer E Cameron; Donald Mercante; Megan O'Brien; Ann M Gaffga; Janet E Leigh; Paul L Fidel; Michael E Hagensee
Journal:  Sex Transm Dis       Date:  2005-11       Impact factor: 2.830

9.  Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J P Fagot; M Mockenhaupt; J N Bouwes-Bavinck; L Naldi; C Viboud; J C Roujeau
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

10.  Cyclin A is required at two points in the human cell cycle.

Authors:  M Pagano; R Pepperkok; F Verde; W Ansorge; G Draetta
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  6 in total

1.  Effect of the HIV nucleoside reverse transcriptase inhibitor zidovudine on the growth and differentiation of primary gingival epithelium.

Authors:  D Mitchell; M Israr; S Alam; J Kishel; D Dinello; C Meyers
Journal:  HIV Med       Date:  2012-01-26       Impact factor: 3.180

2.  HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.

Authors:  D Mitchell; M Israr; S Alam; D Dinello; J Kishel; R Jia; C Meyers
Journal:  HIV Med       Date:  2013-10-31       Impact factor: 3.180

Review 3.  Three-dimensional cell culture models for investigating human viruses.

Authors:  Bing He; Guomin Chen; Yi Zeng
Journal:  Virol Sin       Date:  2016-10-27       Impact factor: 4.327

Review 4.  Oral lichen planus: a microbiologist point of view.

Authors:  Tomás G Villa; Ángeles Sánchez-Pérez; Carmen Sieiro
Journal:  Int Microbiol       Date:  2021-03-10       Impact factor: 2.479

5.  Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.

Authors:  Yamini Pathak; Amaresh Mishra; Gourav Choudhir; Anuj Kumar; Vishwas Tripathi
Journal:  Pharmacol Rep       Date:  2021-05-10       Impact factor: 3.024

6.  Overlapping findings or oral manifestations in new SARS-CoV-2 infection.

Authors:  José Burgos Ponce; Kellen Cristine Tjioe
Journal:  Oral Dis       Date:  2020-07-07       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.